Related Experiment Video
Updated: Jun 15, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
[Adalimumab therapy in Crohn's disdease]
Summary
Adalimumab effectively treats Crohn's disease, even for patients who did not respond to or could not tolerate Infliximab therapy. This biologic agent offers a viable treatment option for refractory Crohn's disease patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Context:
- Crohn's disease (CD) management remains challenging despite existing biologic therapies.
- High rates of primary non-response, secondary loss of response, and intolerance limit Infliximab efficacy in approximately 60% of patients.
- Tumor necrosis factor-alpha (TNF-alpha) inhibitors are crucial in CD treatment.
Purpose:
- To evaluate the efficacy of Adalimumab in Crohn's disease patients, particularly those with prior Infliximab treatment failure.
- To assess Adalimumab's effectiveness in inducing and maintaining remission in CD.
- To determine if Adalimumab is effective regardless of the reason for Infliximab failure.
Summary:
- Adalimumab, a fully-human monoclonal antibody targeting TNF-alpha, demonstrated significant efficacy in randomized placebo-controlled trials for both induction and maintenance of remission in CD.
- The study highlights Adalimumab's effectiveness in patients with a history of Infliximab treatment failure, irrespective of the cause (non-response or intolerance).
- These findings suggest Adalimumab provides a valuable therapeutic option for a substantial proportion of CD patients who do not benefit from Infliximab.
Impact:
- Adalimumab offers a crucial alternative for Crohn's disease patients experiencing treatment failure with Infliximab.
- Improved treatment outcomes and sustained remission are achievable for refractory CD populations.
- This research expands therapeutic strategies for managing complex inflammatory bowel diseases like Crohn's disease.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.